Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10382506" target="_blank" >RIV/00216208:11110/18:10382506 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/18:10382506 RIV/00064203:_____/18:10382506 RIV/00064165:_____/18:10382506

Výsledek na webu

<a href="https://doi.org/10.1007/s00345-018-2450-0" target="_blank" >https://doi.org/10.1007/s00345-018-2450-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00345-018-2450-0" target="_blank" >10.1007/s00345-018-2450-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

Popis výsledku v původním jazyce

Purpose To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. Methods According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. Results Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors &gt; 3 cm or with CIS had earlier cystectomies (HR = 1.79, p = 0.001 and HR = 1.53, p = 0.02, respectively). Patients with tumors &gt; 3 cm, multiple tumors or CIS had earlier T3/T4 or N + cystectomies. In patients who progressed, the timing of cystectomy did not affect the risk of T3/T4 or N + disease at RC. Patients with T3/T4 or N + disease at RC had a shorter disease-specific survival (HR = 4.38, p &lt; 0.001), as did patients with CIS at cystectomy (HR = 2.39, p &lt; 0.001). Patients who progressed prior to cystectomy had a shorter disease-specific survival than patients for whom progression was only detected at cystectomy (HR = 0.58, p = 0.024) Conclusions Patients treated with RC before experiencing progression to muscle-invasive disease harbor better oncological and survival outcomes compared to those who progressed before RC and to those upstaged at surgery. Tumor size and concomitant CIS at diagnosis are the main predictors of surgical treatment while tumor size, CIS and tumor multiplicity are associated with extravesical disease at surgery.

Název v anglickém jazyce

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

Popis výsledku anglicky

Purpose To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. Methods According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. Results Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors &gt; 3 cm or with CIS had earlier cystectomies (HR = 1.79, p = 0.001 and HR = 1.53, p = 0.02, respectively). Patients with tumors &gt; 3 cm, multiple tumors or CIS had earlier T3/T4 or N + cystectomies. In patients who progressed, the timing of cystectomy did not affect the risk of T3/T4 or N + disease at RC. Patients with T3/T4 or N + disease at RC had a shorter disease-specific survival (HR = 4.38, p &lt; 0.001), as did patients with CIS at cystectomy (HR = 2.39, p &lt; 0.001). Patients who progressed prior to cystectomy had a shorter disease-specific survival than patients for whom progression was only detected at cystectomy (HR = 0.58, p = 0.024) Conclusions Patients treated with RC before experiencing progression to muscle-invasive disease harbor better oncological and survival outcomes compared to those who progressed before RC and to those upstaged at surgery. Tumor size and concomitant CIS at diagnosis are the main predictors of surgical treatment while tumor size, CIS and tumor multiplicity are associated with extravesical disease at surgery.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

World Journal of Urology

ISSN

0724-4983

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

1775-1781

Kód UT WoS článku

000448864400010

EID výsledku v databázi Scopus

2-s2.0-85053269432